Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Company profile
Ticker
OASMY
Exchange
Website
CEO
Sven Rohmann
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
OASMY stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
4 Apr 22
424B3
Prospectus supplement
27 Nov 19
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
21 Nov 19
424B3
Prospectus supplement
23 Aug 19
15F-12B
Securities registration termination (foreign)
23 Aug 19
6-K
Nomination committee in Oasmia for the 2019 AGM
21 Aug 19
6-K
Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar
15 Aug 19
EFFECT
Notice of effectiveness
13 Aug 19
25
Voluntary exchange delisting
13 Aug 19
POS AM
Prospectus update (post-effective amendment)
8 Aug 19
Institutional ownership, Q4 2019
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proequities | 0.00 | $0.00 |